Objective: to evaluate the effects of titanium dioxide microcrystals with covalently bonded silver ions and Aloe Vera extract (TIAGIN®) on the Vaginal Health Index Score (VHIS) and Female Sexual Function Index (FSFI) in patients with vaginal de-epithelialization. Materials and methods: we enrolled 45 postmenopausal women with vaginal de-epithelialization, who underwent VHIS evaluation and completed an FSFI test. We recorded their age, age at onset of menopause, parity and Body Mass Index. After this baseline evaluation, patients underwent 30 days of vaginal treatment with one capsule per day of TIAGIN®. After treatment, all patients were evaluated again using the same methods as the pre-treatment phase. Results: after treatment there was significant improvement in all VHIS parameters (elasticity, fluid secretion type and consistency, pH, epithelialization of vaginal mucosa, and moisture) and in the total score (p=0.006). Similarly, after treatment there was also a significant improvement in 4 FSFI areas (lubrication, orgasm, satisfaction, and pain) and in the total score (p=0.005). None of the patients reported any local or systemic side effects during treatment. Conclusions: we observed a significant improvement in both the VHIS and FSFI, which can be considered direct and indirect signs of increased vaginal epithelialization following vaginal treatment with TIAGIN®.
Effects of titanium dioxide microcrystals with covalently bonded silver ions and Aloe Vera extract (TIAGIN®) on the Vaginal Health Index Score (VHIS) and Female Sexual Function Index (FSFI) in patients with vaginal de-epithelialization: a prospective, single-center cohort analysis
Chiofalo B.;
2017-01-01
Abstract
Objective: to evaluate the effects of titanium dioxide microcrystals with covalently bonded silver ions and Aloe Vera extract (TIAGIN®) on the Vaginal Health Index Score (VHIS) and Female Sexual Function Index (FSFI) in patients with vaginal de-epithelialization. Materials and methods: we enrolled 45 postmenopausal women with vaginal de-epithelialization, who underwent VHIS evaluation and completed an FSFI test. We recorded their age, age at onset of menopause, parity and Body Mass Index. After this baseline evaluation, patients underwent 30 days of vaginal treatment with one capsule per day of TIAGIN®. After treatment, all patients were evaluated again using the same methods as the pre-treatment phase. Results: after treatment there was significant improvement in all VHIS parameters (elasticity, fluid secretion type and consistency, pH, epithelialization of vaginal mucosa, and moisture) and in the total score (p=0.006). Similarly, after treatment there was also a significant improvement in 4 FSFI areas (lubrication, orgasm, satisfaction, and pain) and in the total score (p=0.005). None of the patients reported any local or systemic side effects during treatment. Conclusions: we observed a significant improvement in both the VHIS and FSFI, which can be considered direct and indirect signs of increased vaginal epithelialization following vaginal treatment with TIAGIN®.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
